Our studies suggest that SchB treatment reduces hepatic levels of triglyceride and palmitic acid which is known to induce lipotoxicity; the treatment also reduces hepatic fibrosis and activates Nrf2 pathway, which imply its beneficial effect to the treatment of NASH-related fibrosis. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.